BioSkyrb Genomics

Executive Summary

BioSkyrb Genomics is a private biotechnology company based in Durham, North Carolina, specializing in high-fidelity single-cell multiomics. Its proprietary Primary Template-directed Amplification (PTA) technology enables near-complete whole genome amplification from individual cells, integrated with full-length transcriptome and protein analysis. This unified genotype-to-phenotype approach aims to advance research, therapeutic development, and diagnostics. Founded in 2015, the company has developed a platform that addresses key limitations in single-cell genomics, such as amplification bias and coverage gaps. By providing a comprehensive view of cellular heterogeneity, BioSkyrb's solutions are positioned to support applications in oncology, immunology, and rare disease research. The company continues to build its commercial presence in the academic and pharmaceutical research markets, leveraging its differentiated technology to capture value in the growing single-cell multiomics space.

Upcoming Catalysts (preview)

• Q3 2026Commercial launch of integrated multiomics kit70% success
• H2 2026Strategic partnership with pharmaceutical company for drug development50% success
• Q4 2026Series C financing round80% success